Exhibit Hall Theater Talks
PSC-derived therapies face existential scaling challenges: manual cell production is too expensive, and requires 100s of trained scientists to get to enough patients.
But teams waste years trying to get their manual 2D process working in bioreactors - usually resulting in failure.
Mytos iDEM enables existing 2D processes to scale with 10x less labour, and 2.5x less Grade B cleanroom space.
CCO Ignacio Willats will share how regmed teams can solve scalability early, by rapidly transitioning their flask-based process to Mytos iDEM within a handful of runs.